
    
      In Argentina, Faslodex is indicated for treating postmenopausal women with hormone
      receptor-positive locally advanced or metastatic breast cancer with recurrence during or
      after adjuvant anti-oestrogen therapy or disease progression during anti-oestrogen treatment.
      This study will provide information regarding the acceptability and compliance of Argentina
      patients to Faslodex and will provide information regarding the efficacy of this treatment in
      local population.
    
  